A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CONTROLLED TRIAL TOASSESS THE EFFICACY AND SAFETY OF CELLULAR IMMUNOTHERAPY WITH MDR-101 FOR INDUCTIONOF IMMUNE TOLERANCE IN RECIPIENTS OF HLA-MATCHED, LIVING DONOR KIDNEY TRANSPLANTS

Project: Research project

Description

A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CELLULAR IMMUNOTHERAPY WITH MDR-101 FOR INDUCTION OF IMMUNE TOLERANCE IN RECIPIENTS OF HLA-MATCHED, LIVING DONOR KIDNEY TRANSPLANTS
StatusActive
Effective start/end date1/1/1812/31/24

Funding

  • MEDEOR THERAPEUTICS, INC.

Fingerprint

Immune Tolerance
Living Donors
Immunotherapy
Transplants
Kidney
Safety